Optimising outcomes with sunitinib for metastatic renal cell carcinoma (mRCC): focus on anticipating and managing adverse effects – Certificate of Completion

On completion of this program, participants will be better able to:

1. Describe current metastatic renal cell carcinoma (mRCC) treatment options and sunitinib management practices
2. Manage toxicities of sunitinib treatment and interpret their possible prognostic value
3. Recognise the benefits of a multi-disciplinary team approach when treating a patient with RCC
4. Recall second-line treatment options and the current data supporting these options